Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID)

简要总结

主要结局

次要结局

• Bacterial response at the test of cure visit and at the FU visit 28 to 42 days after last dose of study medication(visit 28 to 42 days after last dose)
• Clinical response at during-treatment visit (Day 4-7) and at follow-up 28 to 42 days after last dose((Day 4-7) and at follow-up 28 to 42 days after last dose)
• Reduction from baseline in pain report at the different assessment visits(Over the entire trial period (overall))
• Necessity for modifying antibiotic therapy at the during-treatment visit and TOC visit and necessity for institution of an antibiotic therapy at follow-up(Over the entire trial period (overall))